Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 30, 2017Annals of OncologyOpen Access

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

Luis Paz‐Ares
Luis Paz‐AresUniversidad Complutense de MadridETE.H. TanNational Cancer Centre SingaporeKOKenneth J. O’ByrneTranslational Research Institute

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Paz‐Ares et al. (2017) studied this question.

synapsesocial.com/papers/6aa281df6401f02f7be56a17https://doi.org/10.1093/annonc/mdw611
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients2016 · 238 citations
  2. 2EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib2005 · 3,987 citations